• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

    1/30/25 8:30:00 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GPCR alert in real time by email

    SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.

    Guggenheim SMID Cap Biotech Conference

     Format:Fireside chat and 1x1 meetings
     Date/time:Wednesday, February 5 at 10:30 a.m. ET
     Location:New York, NY
     Webcast link:https://wsw.com/webcast/guggen2/gpcr/2003892
       

    Leerink Global Healthcare Conference

     Format:Fireside chat and 1x1 meetings
     Date/time:Monday, March 10 at 1:00 p.m. ET
     Location:Miami, FL
     Webcast link:https://wsw.com/webcast/leerink38/gpcr/2218364
       

    Jefferies Biotech on the Bay Summit

     Format:1x1 meetings
     Date:Tuesday, March 11
     Location:Miami, FL
       

    The live and archived webcasts of the fireside chats will be accessible from the company's website at https://ir.structuretx.com/events-presentations/events and replays will be available for 90 days.

    About Structure Therapeutics 

    Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.

    Investors:

    Danielle Keatley

    Structure Therapeutics Inc.

    [email protected]

    Media:

    Dan Budwick

    1AB

    [email protected]



    Primary Logo

    Get the next $GPCR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GPCR

    DatePrice TargetRatingAnalyst
    5/2/2025$60.00Buy
    Citigroup
    2/28/2025Outperform
    William Blair
    1/8/2025$50.00Buy
    Stifel
    12/4/2024$80.00Buy
    H.C. Wainwright
    9/23/2024$118.00Overweight
    Morgan Stanley
    5/21/2024$65.00Overweight
    JP Morgan
    4/9/2024$65.00Overweight
    Cantor Fitzgerald
    10/19/2023$90.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $GPCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Structure Therapeutics with a new price target

    Citigroup initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $60.00

    5/2/25 8:15:19 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Structure Therapeutics

    William Blair initiated coverage of Structure Therapeutics with a rating of Outperform

    2/28/25 7:24:16 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Structure Therapeutics with a new price target

    Stifel initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $50.00

    1/8/25 7:51:31 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Lin Xichen covered exercise/tax liability with 12,846 units of Ordinary Shares, decreasing direct ownership by 6% to 204,327 units (SEC Form 4)

    4 - Structure Therapeutics Inc. (0001888886) (Issuer)

    8/20/25 5:00:11 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF TECHNOLOGY OFFICER Ma Yingli covered exercise/tax liability with 4,470 units of Ordinary Shares, decreasing direct ownership by 4% to 118,704 units (SEC Form 4)

    4 - Structure Therapeutics Inc. (0001888886) (Issuer)

    8/20/25 5:00:16 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by See Remark 1 Fmr Llc

    4 - Structure Therapeutics Inc. (0001888886) (Issuer)

    8/1/25 9:34:05 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

    Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive positioning and Phase 3 program Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025 Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at least 2027 SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceu

    8/6/25 4:01:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

    SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL. "The amylin receptor is rapidly gaining clinical validation as a key target in obesity, driven by encouraging data from injectable peptide programs. We believe ACCG-2671 is well-positioned and differentiated as an oral small molecule frontrunner that is expected to enter clinical development by the end of

    6/20/25 7:30:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

    SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences in June. Jefferies Global Healthcare Conference Format: Fireside chat and 1x1 meetingsDate/time: Thursday, June 5 at 8:10 a.m. ETLocation: New York, NY Goldman Sachs Global Healthcare Conference Format: Fireside chat and 1x1 meetingsDate/time: Wednesday, June 11 at 10:40 a.m. ETLocation: Miami, FL The live and archived webcasts of the fireside chats will be accessible from the compa

    5/29/25 4:05:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Structure Therapeutics Inc.

    SCHEDULE 13G - Structure Therapeutics Inc. (0001888886) (Subject)

    8/18/25 5:02:11 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

    SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    8/14/25 11:26:18 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

    SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    8/14/25 8:46:39 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Leadership Updates

    Live Leadership Updates

    View All

    Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

    SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase

    9/17/24 4:05:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Appoints Angus C. Russell to Board of Directors

    SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of Shire plc and brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry. "Structure is at an important moment in its evolution as we prepare to advance our oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity," said Raymond Steve

    8/27/24 4:05:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

    Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements. "We have continued our momentum and are on track to report topline data from our fully-enrolled Phase 2a study of GSBR-129

    8/10/23 4:05:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 5:46:12 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Structure Therapeutics Inc.

    SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 10:26:11 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 9:33:27 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Financials

    Live finance-specific insights

    View All

    Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

    Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671. Amy

    12/17/24 4:01:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

    First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today

    11/13/24 4:05:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

    Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first pati

    11/13/24 4:01:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care